Saniona AB (publ) (SANION.ST)
SEK 6.4
(4.07%)
SEK 6.4
(4.07%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -81.06 Million SEK | 64.85% |
| 2022 | -225.71 Million SEK | 45.16% |
| 2021 | -411.57 Million SEK | -158.24% |
| 2020 | -159.37 Million SEK | -53.38% |
| 2019 | -103.9 Million SEK | -91.69% |
| 2018 | -54.2 Million SEK | 5.22% |
| 2017 | -57.19 Million SEK | -1476.08% |
| 2016 | 4.15 Million SEK | 114.8% |
| 2015 | -28.07 Million SEK | -239.97% |
| 2014 | -8.25 Million SEK | -385.76% |
| 2013 | -1.7 Million SEK | 22.16% |
| 2012 | -2.18 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -13.65 Million SEK | 26.02% |
| 2024 Q2 | -16.04 Million SEK | -17.52% |
| 2023 Q3 | -18.35 Million SEK | 15.87% |
| 2023 Q2 | -21.81 Million SEK | -3.76% |
| 2023 Q4 | -18.45 Million SEK | -0.51% |
| 2023 FY | -79.34 Million SEK | 64.85% |
| 2023 Q1 | -21.02 Million SEK | 6.98% |
| 2022 Q2 | -91.76 Million SEK | 31.11% |
| 2022 FY | -225.71 Million SEK | 45.16% |
| 2022 Q1 | -133.2 Million SEK | -6.66% |
| 2022 Q4 | -22.6 Million SEK | -203.45% |
| 2022 Q3 | 21.85 Million SEK | 123.81% |
| 2021 FY | -411.57 Million SEK | -158.24% |
| 2021 Q1 | -94.13 Million SEK | -50.89% |
| 2021 Q4 | -124.88 Million SEK | -41.59% |
| 2021 Q3 | -88.2 Million SEK | 14.84% |
| 2021 Q2 | -103.56 Million SEK | -10.02% |
| 2020 FY | -159.37 Million SEK | -53.38% |
| 2020 Q4 | -62.38 Million SEK | -52.57% |
| 2020 Q1 | -30.6 Million SEK | -8.83% |
| 2020 Q2 | -25.49 Million SEK | 16.71% |
| 2020 Q3 | -40.89 Million SEK | -60.41% |
| 2019 Q2 | -20.58 Million SEK | 29.37% |
| 2019 Q4 | -28.12 Million SEK | -7.98% |
| 2019 Q3 | -26.04 Million SEK | -26.5% |
| 2019 FY | -103.9 Million SEK | -91.69% |
| 2019 Q1 | -29.14 Million SEK | 14.93% |
| 2018 Q4 | -34.26 Million SEK | -271.99% |
| 2018 Q2 | -24.13 Million SEK | -53.43% |
| 2018 Q1 | -15.73 Million SEK | 5.23% |
| 2018 Q3 | 19.92 Million SEK | 182.54% |
| 2018 FY | -54.2 Million SEK | 5.22% |
| 2017 Q2 | -17.87 Million SEK | -136.08% |
| 2017 Q4 | -16.59 Million SEK | -9.61% |
| 2017 Q1 | -7.57 Million SEK | 49.61% |
| 2017 Q3 | -15.14 Million SEK | 15.29% |
| 2017 FY | -57.19 Million SEK | -1476.08% |
| 2016 Q2 | -13.5 Million SEK | -1176.18% |
| 2016 Q1 | -1.05 Million SEK | 80.14% |
| 2016 FY | 4.15 Million SEK | 114.8% |
| 2016 Q4 | -15.02 Million SEK | -144.54% |
| 2016 Q3 | 33.74 Million SEK | 349.92% |
| 2015 Q3 | -10.85 Million SEK | -59.97% |
| 2015 Q4 | -5.32 Million SEK | 50.93% |
| 2015 FY | -28.07 Million SEK | -239.97% |
| 2015 Q1 | -5.1 Million SEK | 18.25% |
| 2015 Q2 | -6.78 Million SEK | -33.0% |
| 2014 Q3 | -2.32 Million SEK | -176.43% |
| 2014 FY | -8.25 Million SEK | -385.76% |
| 2014 Q4 | -6.24 Million SEK | -168.82% |
| 2014 Q1 | -889 Thousand SEK | 0.0% |
| 2014 Q2 | -840 Thousand SEK | 5.51% |
| 2013 FY | -1.7 Million SEK | 22.16% |
| 2012 FY | -2.18 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| 2cureX AB (publ) | -36.36 Million SEK | -122.933% |
| Abliva AB (publ) | -96.54 Million SEK | 16.037% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 26.912% |
| AcouSort AB (publ) | -17.48 Million SEK | -363.573% |
| Active Biotech AB (publ) | -46.48 Million SEK | -74.393% |
| Alzinova AB (publ) | -16.52 Million SEK | -390.649% |
| Amniotics AB (publ) | -29.07 Million SEK | -178.833% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -83.505% |
| Aptahem AB (publ) | -10.1 Million SEK | -702.246% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -453.723% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 67.442% |
| BioInvent International AB (publ) | -369.94 Million SEK | 78.087% |
| BioArctic AB (publ) | 252.64 Million SEK | 132.087% |
| Biosergen AB | -27.26 Million SEK | -197.323% |
| Biovica International AB (publ) | -126.07 Million SEK | 35.7% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -46.282% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 78.911% |
| Camurus AB (publ) | 532.35 Million SEK | 115.228% |
| Cantargia AB (publ) | -290.01 Million SEK | 72.048% |
| Corline Biomedical AB | -1.78 Million SEK | -4433.837% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -302.527% |
| CombiGene AB (publ) | -36.3 Million SEK | -123.288% |
| Cyxone AB (publ) | -21.66 Million SEK | -274.244% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -600.891% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 44.691% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 75.042% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -374.168% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 23.498% |
| Fluicell AB (publ) | -26.87 Million SEK | -201.592% |
| Genovis AB (publ.) | 54.22 Million SEK | 249.5% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 29.553% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 89.719% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 39.781% |
| Mendus AB (publ) | -100.65 Million SEK | 19.459% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 55.154% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -94.48% |
| I-Tech AB | 24.43 Million SEK | 431.758% |
| Intervacc AB (publ) | -93.57 Million SEK | 13.373% |
| Kancera AB (publ) | -65.04 Million SEK | -24.635% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -2212.839% |
| LIDDS AB (publ) | -40.67 Million SEK | -99.304% |
| Lipum AB (publ) | -37.25 Million SEK | -117.601% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -555.283% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 550.136% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -394.269% |
| Nanologica AB (publ) | -69.96 Million SEK | -15.868% |
| NextCell Pharma AB | -43.17 Million SEK | -87.772% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 68.015% |
| OncoZenge AB (publ) | -15.9 Million SEK | -409.779% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -1167.978% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -422.595% |
| Simris Alg AB (publ) | -36.63 Million SEK | -121.277% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -90.719% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -9493.491% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -238.416% |
| SynAct Pharma AB | -224.49 Million SEK | 63.89% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 74.786% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 73.886% |
| Xintela AB (publ) | -57.23 Million SEK | -41.628% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 55.154% |
| Ziccum AB (publ) | -21.56 Million SEK | -275.997% |